Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021176 · ClinicalTrials.gov registry record · Phase 1
Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell
A Phase 1 study, sponsored by Pennington Biomedical Research Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01021176 is a Phase 1 study that was terminated before completion, run by Pennington Biomedical Research Center. The registered enrollment target is 12 participants.
The verdict
NCT01021176, a Phase 1 study, was terminated before completion, sponsored by Pennington Biomedical Research Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the blood pressure medication, diltiazem, will temporarily decrease the sense of smell when given in a nasal spray which will then reduce food intake.
Interventions
- DRUG Diltiazem
- OTHER Placebo spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021176
The ClinicalTrials.gov registry entry for NCT01021176 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diltiazem is the first listed.
NCT01021176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01021176 about?
NCT01021176 is a clinical study titled "Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell". The purpose of this study is to determine whether the blood pressure medication, diltiazem, will temporarily decrease the sense of smell when given in a nasal spray which will then reduce food intake.
What is the current status of trial NCT01021176?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT01021176?
The interventions under investigation include: Diltiazem (DRUG), Placebo spray (OTHER).
Who is sponsoring clinical trial NCT01021176?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.